TSTickerStarGet alerts

Evommune Announces $30 Million Common Stock Private Placement

Evommune entered into a securities purchase agreement to sell 4,966,889 shares of common stock at $6.04 per share to a select group of healthcare institutional investors, with anticipated gross proceeds of approximately $30 million before transaction-related expenses. The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions. Net proceeds are intended to advance clinical development programs, including EVO570, and for general corporate pu...

Share this story

Key takeaways

  • Evommune entered into a securities purchase agreement to sell 4,966,889 shares of common stock in a private placement.

  • The purchase price is $6.04 per share, with anticipated gross proceeds of approximately $30 million before deducting transaction-related expenses.

  • The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions.

  • The financing includes participation from new and existing institutional investors, including Adage Capital Partners, L.P., Balyasny Asset Management, Defilade Capital Management, OrbiMed, Squadron Capital Management and other fundamental healthcare dedicated funds.

  • Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents, and Oppenheimer & Co. Inc. acted as capital markets advisor.

  • Net proceeds are intended to advance clinical development programs, including EVO570, the newly in-licensed oral VAV1-directed molecular glue degrader, and for general corporate purposes.

  • The securities are not registered under the Securities Act of 1933; concurrently, Evommune entered into a registration rights agreement to register the resale of the shares with the SEC.

Key metrics

Common shares to be sold in private placement
4,966,889 shares
Purchase price per share
$6.04
Anticipated gross proceeds
Approximately $30 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow EVMN in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert